Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML
对于预后不良的MDS/AML患者,先进行Venetoclax/FluBu2 RIC移植,随后进行全口服Venetoclax/地西他滨维持治疗。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025018631
Garcia, Jacqueline S; Kim, Haesook T; Murdock, H Moses; Bosch-Vilaseca, Anna; Panaro, Kevin M; Lim, Felicia; Fiorilla, Jade; Auriemma, Elise; Brock, Jennifer; Gooptu, Mahasweta; Ho, Vincent T; Cutler, Corey S; Shapiro, Roman; Kelkar, Amar H; Abel, Gregory A; DeAngelo, Daniel J; Stone, Richard M; Bat-Erdene, Denbaa; Ryan, Jeremy; Fell, Geoffrey; Letai, Anthony; Ritz, Jerome; Lindsley, R Coleman; Antin, Joseph H; Soiffer, Robert J